STM2457, a Mettl3 inhibitor, reduces Egfr's m6A modification to increase HCC cells sensitivity to lenvatinib177, and UZH1A selectively binds to Mettl3 mRNA to exert antitumor effects in leukemia and osteosarcoma178. Here, METTL3 is linked to leukemia.